ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Health Care · Biotechnology · NASDAQ
Arrowhead Pharmaceuticals is a clinical-stage biotechnology company leveraging its proprietary RNA interference (RNAi) platform to develop potent medicines that silence disease-causing genes.
What ARROWHEAD PHARMACEUTICALS, INC. does
Arrowhead Pharmaceuticals is a biopharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them. The company utilizes a proprietary RNA interference (RNAi) platform to design therapeutics that inhibit the production of specific disease-causing proteins. Its clinical-stage pipeline targets a range of conditions, including liver-related diseases, cardiovascular health, and pulmonary disorders.
Themes: gene silencing, RNAi therapeutics, biopharmaceutical R&D, precision medicine
Fundamentals
- Price$89.12 as of 2026-08-26 close
- Market cap$12.6B as of 2026-08-26
- 1-year return+320.8% 2025-08-26 close $21.18 → 2026-08-26 close $89.12
- P/En/a negative earnings
- Net margin-47.8% as of 2026-08-26
- Gross margin+100.0% as of 2026-08-26
- ROE-60.5% as of 2026-08-26
- Debt / equity2.70 as of 2026-08-26
- Revenue growth (YoY)+16.9% as of 2026-08-26
- Revenue CAGR (3y)+50.5% SEC XBRL
- Beta1.65 as of 2026-08-26
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How ARWR compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-26
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-26
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ARWR is not currently in any published Top 10 list. Its scores are below.
Long-term score
43.6 #1171 of 1,608 scored · #141 of 198 in Health Care
Growth 84th (3-year revenue CAGR 50.5%, revenue growth year over year 16.9%) and long-term trend 83rd (over the past 12 months this stock beat the market by 310.0 percentage points); weakest is profitability (4th, return on equity -60.5%, operating margin -33.8%).
Short-term score
54.4 #478 of 1,696 scored · #94 of 239 in Health Care
Trend 73rd: a "golden cross" — its 50-day average is above its 200-day; setup 57th: day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move; weakest is catalysts 30th: open-market insider buys in 90 days 1, analysts' average price target is unchanged from the prior reading.
Scores as of 25 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How ARROWHEAD PHARMACEUTICALS, INC. looks technically
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is trading 29.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 247 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day high about 17 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 50% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 29.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +29.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $83.28 | $83.28 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $69.06 | $69.06 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 83.78. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 247 trading days ago — a "golden cross", a bullish long-term signal | 247 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 57.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($83.78 to $90.97) — its "stochastic" reading is 74 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 74.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $95.49 | $95.49 |
|---|---|---|
| From the 52-week high | it is 6.7% below its 52-week high (its highest price of the past year) | -6.7% |
| Above the 52-week low | it is 349.8% above its 52-week low (its lowest price of the past year) | +349.8% |
| Below the 52-week high | it is 6.7% below its highest point of the past year | 6.7% |
| Since a 20-day breakout | it made a new 20-day high about 17 trading days ago | 17 sessions |
| Since a 55-day breakout | it made a new 55-day high about 17 trading days ago | 17 sessions |
| All-time high | its highest closing price on record is $95.49 (set on 2026-07-22) | $95.49 |
| Given back of the 52-week move | over the past year its closes ranged ($20.71 to $89.59), and it has given back essentially none of its rise from last year’s low — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $44.82 to $47.02. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.7% |
| From the all-time high | it is 6.7% below its all-time high | -6.7% |
| Nearest price level | it is trading 5.6% above a support level at $84.16 — a price it turned at twice since 2026-06-18, most recently on 2026-08-14. Since 2024-08-26 it has 16 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.6% |
| All-time low | its lowest closing price on record is $1.20 (set on 2016-12-21) | $1.20 |
| Above the all-time low | it is 7326.7% above its all-time low | +7,327% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.31 between its high and its low — about 3.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.31 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $84.81 and $90.22 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $84.81 – $87.52 – $90.22 |
| Typical daily range (% of price) | its price moves about 3.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.7% |
| Stretch from the 200-day average | it is trading 6.1 daily ranges above its 200-day average price (29.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 50% of its 30-day average | 0.50× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-26 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Open gap | it gapped 14.6% above the previous close 25 sessions ago and has not traded back through the level it left behind at 74.52 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +14.6% |
| Gap filled | a 2.5% gap up opened on 2026-08-07 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 9 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +2.76% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.4 percentage points (the stock gained 4.1% while the market gained 3.7%) | +0.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 11.2 percentage points (the stock gained 13.3% while the market gained 2.1%) | +11.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 29.5 percentage points (the stock gained 40.6% while the market gained 11.1%) | +29.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 302.0 percentage points (the stock gained 320.8% while the market gained 18.7%) | +302.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.3% of the share price, which is taken to mean a barrier that gives way easily. | +13.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 26% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $70.99 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | +25.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $87.85 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | +1.4% |
Price levels it has turned at before
ARWR last closed at $89.12 on 2026-08-26. Since 2024-08-26 it has turned at 16 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $84.16 | Support | 5.6% below the last close | turned there twice · 2026-06-18 to 2026-08-14 |
| $81.81 | Support | 8.2% below the last close | turned there twice · 2026-05-14 to 2026-08-03 |
| $76.70 | Support | 13.9% below the last close | turned there four times · 2026-01-06 to 2026-06-26 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $83.78.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 7 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a Bollinger Band volatility squeeze · beating the market · Stretched far above its 200-day average (6+ daily ranges) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$110.18 range $100.00 – $126.00; median $104.00
Analyst estimates, as of 2026-08-25. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ARWR
- Consensus EPS estimate-$1.52 next reporting period, as of 2026-08-25
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant history of operating losses and recurring negative cash flows with no assurance of achieving future profitability.","Dependence on successful clinical development and regulatory approval for its pipeline candidates, which carry inherent risks of failure.","Reliance on strategic partnerships for development and commercialization, which exposes the company to risks regarding partner priorities and performance."]
What changed in the latest 10-Q
AI-assisted comparison of ARWR's 10-Q filed 2026-05-07 against the prior one filed 2026-02-05.
Management's Discussion & Analysis (MD&A)
- Notes:
- Both texts appear truncated at the same point ('Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in "'); full section comparison not possible
- Based on the available truncated portions, the two filings contain identical text in the Forward-Looking Statements section
Risk Factors
- Added:
- Balance sheet as of March 31, 2026 added (newer filing 2026-05-07)
- Consolidated statements of operations for six months ended March 31, 2026 and 2025 added (newer filing)
- Consolidated statements of stockholders' equity extended to include March 31, 2026 balances (newer filing)
- Convertible notes, net of $681,940 thousand added to long-term liabilities as of March 31, 2026 (newer filing)
- Deferred revenue, net of current portion of $48,615 thousand added to long-term liabilities as of March 31, 2026 (newer filing)
- Loss on equity method investment of $6,719 thousand for six months ended March 31, 2026 (newer filing)
- Gain on VIE's sale of IPR&D assets of $19,000 thousand for six months ended March 31, 2026 (newer filing)
- Issuance of common stock in follow-on offering, net of issuance costs of $116,607 thousand in Q2 2026 (newer filing)
- Issuance of pre-funded warrants of $99,998 thousand in Q2 2026 (newer filing)
- Purchase of Capped Calls related to 2026 Convertible Note of $47,880 thousand in Q2 2026 (newer filing)
- Change in ownership interest in consolidated VIE with net impact of $3,120 thousand and noncontrolling interest adjustment of $3,133 thousand in Q2 2026 (newer filing)
- Gain on VIE's sale of IPR&D assets attributable to noncontrolling interest of $7,629 thousand in Q2 2026 (newer filing)
- Removed:
- Balance sheet as of December 31, 2025 removed (older filing 2026-02-05)
- Consolidated statements of operations for three months and six months ended December 31, 2025 and 2024 removed
- Consolidated statements of stockholders' equity for periods ending December 31, 2025 removed
- Consolidated statements of cash flows for three months ended December 31, 2025 and 2024 removed
- Reworded:
- Operating expenses section heading changed from 'Selling, general and administrative' in older filing to split between 'Selling, general and administrative' and 'Research and development' line items (newer filing maintains both)
- Comprehensive income statement presentation title changed from 'Consolidated Statements of Operations and Comprehensive Income (Loss)' (older) to 'Consolidated Statements of Operations and Comprehensive (Loss) Income' (newer)
- Notes:
- The two filings represent different reporting periods: the newer filing (2026-05-07) covers the quarter ended March 31, 2026, while the older filing (2026-02-05) covered the quarter ended December 31, 2025. The differences reflect period-specific financial activity rather than restatements.
- Older filing contained cash flow statement that is absent from newer filing excerpt provided.
- The comparison is of financial statements sections, not risk factors section despite the request being for 'Risk Factors' - the actual Risk Factors text was not fully provided in either filing excerpt.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($1M) — 2 selling insiders
- Last 90 days0 buys · 2 sells ($1M) — 2 selling insiders
- Last 180 days0 buys · 8 sells ($4M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-18. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ARWR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding ARWR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 33,406,842
- Reported value $2,094,608,965
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ARWR had 9,656,078 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ARWR had 6.84% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.85 days to cover at the same settlement.
- Reported short interest (shares) 9,656,078
- Short interest (% of shares outstanding) 6.84%
- Prior settlement (shares) 9,635,297
- Reported change 0.22%
- Days to cover (reported) 3.85
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alnylam Pharmaceuticals (ALNY)
- Ionis Pharmaceuticals (IONS)
- Dicerna Pharmaceuticals (acquired by Novo Nordisk)
- BridgeBio Pharma (BBIO)
- Regeneron Pharmaceuticals (REGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ARWR vs…
ARROWHEAD PHARMACEUTICALS, INC. is found in…
ARWR ranks in…
Frequently asked questions
What does ARROWHEAD PHARMACEUTICALS, INC. (ARWR) do?
Arrowhead Pharmaceuticals is a biopharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them. The company utilizes a proprietary RNA interference (RNAi) platform to design therapeutics that inhibit the production of specific disease-causing proteins. Its clinical-stage pipeline targets a range of conditions, including liver-related diseases, cardiovascular health, and pulmonary disorders.
What sector is ARROWHEAD PHARMACEUTICALS, INC. (ARWR) in?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are ARROWHEAD PHARMACEUTICALS, INC.'s (ARWR) competitors?
Notable peers of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Dicerna Pharmaceuticals (acquired by Novo Nordisk), BridgeBio Pharma and Regeneron Pharmaceuticals. This peer set is informational only — not financial advice.
Is ARROWHEAD PHARMACEUTICALS, INC. (ARWR) overbought or oversold right now?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ARWR come from?
Fundamentals and prices come from market data, as of 2026-08-26; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.